# Brian Slingerland

> Brian Slingerland is a biotechnology founder and executive whose career moved from technology investment banking to building companies at the intersection of business and cancer biology. After co-founding Qatalyst Partners, he co-founded and led Stemcentrx through its 2016 acquisition by AbbVie, and today serves as CEO of Convergent Genomics and a board member of Link Cell Therapies.

- **Role:** Chief Executive Officer at Convergent Genomics; Board Member at Link Cell Therapies
- **Organizations:** Convergent Genomics, Link Cell Therapies, Stemcentrx, Qatalyst Partners, Goldman Sachs, Credit Suisse First Boston
- **Education:** Bachelor's degree in Finance, Virginia Tech, Pamplin College of Business
- **Known for:** Co-founded Qatalyst Partners, an independent technology-focused investment bank., Co-founded and led Stemcentrx as CEO from its 2008 formation through its 2016 acquisition by AbbVie., Built Stemcentrx capabilities spanning target discovery and validation, GMP manufacturing, and clinical development.

## Career timeline

- **2000** — Graduated from Virginia Tech with a finance degree and moved to California for an analyst role at Credit Suisse First Boston.
- **2004** — Joined Goldman Sachs, where he later rose to managing director.
- **2008** — Left Goldman Sachs and co-founded technology investment bank Qatalyst Partners.
- **2008** — Co-founded Stemcentrx with cancer researcher Scott Dylla and became its CEO.
- **2016** — Stemcentrx was acquired by AbbVie for approximately $5.8 billion upfront, with up to $4 billion in additional milestone payments.
- **2016** — Delivered the keynote address at Virginia Tech's Pamplin College of Business commencement.
- **2026** — Serves as CEO of Convergent Genomics and as a board member of Link Cell Therapies.

## Achievements

- Co-founded Qatalyst Partners, an independent technology-focused investment bank.
- Co-founded and led Stemcentrx as CEO from its 2008 formation through its 2016 acquisition by AbbVie.
- Built Stemcentrx capabilities spanning target discovery and validation, GMP manufacturing, and clinical development.
- Led Stemcentrx while it formed target- and platform-specific partnerships with Pfizer and Bristol Myers Squibb.
- Delivered the 2016 keynote address for Virginia Tech's Pamplin College of Business commencement.
- Currently leads Convergent Genomics and serves on the board of Link Cell Therapies.

## Latest updates

- **2025-12** — Link Cell Therapies publicly launched from stealth with a $60 million Series A; Slingerland is listed as a board member.
- **2023-08** — Convergent Genomics announced publication of a multi-center study of its UroAmp genomic urine test in Clinical Cancer Research.
- **2023-05** — Convergent Genomics presented studies on urinary comprehensive genomic profiling at the American Urological Association annual meeting.

## Links

- Website: https://convergentgenomics.com
- LinkedIn: https://www.linkedin.com/in/brian-slingerland-a7a14b35

---

Profile page: https://yespress.io/brian-slingerland
Published by YesPress — https://yespress.io
Last updated: 2026-08-26